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p = 0.025), and DDFS (HR 0.58, 95% CI 0.40–0.85; 
p = 0.005), with a consistent but not statistically significant 
effect in LRFS. This effect was not seen in familial cases 
(HR > 1.0), and family history was found to interact with 
HT in BCS  (p(interaction) = 0.0067) (BC-death) and DDFS 
 (p(interaction) = 0.0070). There was phenotypic heterogeneity 
between HT-associated tumors in familial and non-familial 
cases, particularly on estrogen receptor (ER) status, although 
the interaction between HT and family history appears to be 
at least partially independent of these markers (p = 0.0370 
after adjustment for standard prognostic factors). If con-
firmed by further studies, our results suggest that family his-
tory should be taken into consideration in clinical counseling 
before beginning a HT regimen.
Abstract Long term use of postmenopausal hormone ther-
apy (HT) has been reported to increase breast cancer risk. 
On the other hand, observational studies suggest that breast 
cancers diagnosed during HT may have a more favorable 
prognosis. While family history is a risk factor for breast 
cancer, and genetic factors also influence prognosis, the role 
of family history in combination with HT use has been little 
studied. We investigated the relationship between HT, fam-
ily history, and prognosis in 584 (267 exposed) familial and 
952 (460 exposed) non-familial breast cancer cases, using 
three survival end points: death from breast cancer (BCS), 
distant disease free survival (DDFS), and local recurrence 
free survival (LRFS). Among non-familial cases, HT was 
associated with better BCS (HR 0.63, 95% CI 0.41–0.94; 
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Introduction
Breast cancer is the most common cancer for women world-
wide and one of the leading causes of death. In Finland there 
were on an average 4564 new cases of female breast cancer 
diagnosed between 2010 and 2014 (age standardised inci-
dence 90.1 per 100,000) and the incidence of breast cancer 
is increasing [1], although the age-standardized mortality 
rate has slightly decreased in recent years.
Hormonal factors play a significant role in the occurrence 
and prognosis of breast cancer. Exposure to ovarian hor-
mones throughout life affects the risk of developing breast 
cancer. Early menarche, delayed menopause, high endog-
enous levels of estrogens, nulliparity, a late age of giving 
birth to the first child, alcohol consumption, and high body-
mass index in postmenopausal women all increase the risk 
of breast cancer [2].
Menopausal symptoms affect more than 50% of women. 
Hormone therapy (HT) with estrogen or combining estrogen 
with progestin has been used by postmenopausal women 
for symptom relief [3]. The associations between risk of 
breast cancer and use of HT have been investigated intensely, 
the overall consensus being that the use of HT regimens 
increased the risk of breast cancer. A large meta-analysis 
comprising 51 individuals studies indicated that breast can-
cer risk was proportional to the duration of HT use with no 
significant differences between different regimens, however 
information of used regimens were available for only a pro-
portion of the participants (39%) [4]. In contrast a study by 
Olsson et al. indicated a significantly elevated risk of devel-
oping breast cancer after combined estrogen and progestore 
use, while estrogen use only did not increase the risk [5]. 
More recently the large placebo-controlled trial by the 2002 
Women’s Health Initiative (WHI) indicated that the breast 
cancer risk may be different with estrogen only and estrogen 
combined with progesterone: breast cancer risk was signifi-
cantly increased during the intervention in the combined 
treatment arm, but on the contrary decreased in the estrogen 
only arm [6–8].
Most observational studies show that the breast cancers 
diagnosed during HT are less aggressive and have a more 
favorable prognosis. Breast cancers associated with HT have 
been associated to lobular or tubular histology, small size, 
low grade, and estrogen receptor positivity and diagnosed 
at an earlier stage [4, 9–19]. In general, prognosis seems to 
be more favorable among patients with HT-related breast 
cancer [18, 20–23]. Again, however, the WHI trials indicate 
a significant biological difference between estrogen-only and 
estrogen–progestin combination HT: combination thera-
pies associated with larger, progesterone receptor-negative 
tumors, whereas in the estrogen-only group, tumors were 
more often HER2 positive, moderately differentiated (grade 
2) and of lobular histology [7].
Women with a family history of breast cancer have an 
elevated baseline risk of breast cancer. The interaction of 
family history and HT has been evaluated in several stud-
ies, with mixed results. Some studies have reported asso-
ciation between HT use and increased risk of breast can-
cer also among women with positive family history, while 
others have failed to observe such an interaction [4, 24, 
25]. The 2015 WHI study included a substantial fraction 
(11.8–14.2%) of cases with family history, but association 
between family history and tumor characteristics in the 
estrogen-only and estrogen–progestin groups was not inves-
tigated [7].
Tumor characteristics and prognosis have not been exten-
sively studied in cases developing during HT in women with 
a family history of breast cancer. A study by Sellers et al. 
reported that women with a family history of breast cancer 
who used HT had a significantly lower any-cause mortality 
than did women who had never used HT, but this effect was 
not replicated when death from breast cancer was used as 
the end-point of the analysis [24]. The relationship between 
HT use and prognosis in patients with a family history of 
breast cancer survival therefore remains unclear at this time.
The aim of the present study was to investigate whether 
HT use associates with the tumor characteristics and prog-
nosis of breast cancer in women with family history, by 
linking a well characterized cohort of breast cancer patients 
with data to a comprehensive database of previous HT use 




The breast cancer cases in this study have been recruited in 
four patient series containing 2815 patients in total. Three of 
these series are unselected (consecutively recruited, includ-
ing both familial and sporadic cases), and the fourth is based 
on family history. The first two series of 884 unselected 
cases were collected at the Department of Oncology between 
April 1997 to March 1998 and from January 2000 to June 
2000 [26, 27], covering 79% of all newly diagnosed cases 
treated at the Department during the collection period. The 
third series of 986 unselected patients was collected at the 
Department of Surgery from November 2001 to February 
2004 [28], with 87% coverage of all newly diagnosed cases. 
The study population also includes an additional series of 
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945 familial breast cancer patients (both index cases and rel-
atives) from an ongoing collection at the Helsinki University 
Hospital’s Departments of Oncology and Clinical Genetics 
starting in 1995 [29, 30]. The median time between diagno-
sis and study entry was 9.7 months among the familial cases. 
All patients were recruited with written informed consent.
From these cases a sample of 1536 postmenopausal 
familial and non-familial patients with invasive breast can-
cer (ICD C50; malignant neoplasm of breast) diagnosed 
at the age of 50 or later has been selected for this study. 
Cases with breast cancer in-situ only were excluded as 
well as cases with diagnosis of breast cancer later than 
1.1.2010. Cases with germline BRCA-1 or BRCA-2 muta-
tions were excluded from cases with family history, as 
previously described [31]. The selection process of these 
1536 cases, of whom 727 were classified as current users 
of HT at the time of diagnosis, is described in detail in 
Fig. 1.
Series 1: unselected 
(containing both non-
familial and familial) 
patients from the 
Department of Oncology, 
Helsinki University Central 
Hospital 1997-1998 and 
2000
n=884
Series 2: unselected 
(containing both non-familial 
and familial) patients from the 
Department of Surgery since 
2001 to 2004
n=986
Series 3: familial patients 
from the Department of 
Clinical Genetics, Helsinki 
University Central Hospital
n=945
All patients having a diagnosis of invasive breast cancer at or over 50 years of age (in situ 
cases were excluded as well as BRCA-1 and BRCA-2 related cases and cases with diagnosis 
of breast cancer before 1.7.1994 or after 1.1.2010 )
Patients with non-familial 
breast cancer
n=952












2. HRT use for less than 3 
months 
3. Past users
4. used only vaginal HRT 





2. HRT use for less than 3 
months
3. Past users
4. used only vaginal HRT 
regimen or progestin-only, 
or LNG-IUS-only users
Fig. 1  Flow diagram describing the collection and selection of cases in the study
324 R. Fagerholm et al.
1 3
Out of the 1536 patient sample, 952 were cases with non-
familial breast cancer and 584 with familial breast cancer. 
Family history was ascertained by patient interviews first, 
with verification by population registry, hospital records 
and/or the Finnish Cancer Registry as previously described 
[31]. Breast cancer families were identified by the selection 
criterion of at least two first- or second-degree relatives with 
breast or ovarian cancer in the family.
This study has been approved by the ethics committee of 
the Helsinki University Hospital.
Characterization of HT use
The users of HT were identified using the National Medical 
Reimbursement Registry of the Social Insurance Institution 
during the period from the beginning of 1994 to the end of 
2009. The registry covers practically 100% of all HT users 
because HT is available only with medical prescription in 
Finland and women themselves finance a part of it. Of all 
these patients, we included all women who used HT at least 
6 months (who had bought HT regimens at least twice at 3 
months intervals) in this study. Patients who had bought a 
HT regimen only once (a dose for 3 months or less) were 
considered as non-users, because this group of women might 
include individuals who had only bought HT regimens, but 
not used them.
In this study, we compared non-users and current-users of 
systemic HT (use at the time of or within 12 months before 
breast cancer diagnosis). Patients who had used only vaginal 
estrogen were considered as non-users since vaginal HT has 
no documented effect on breast cancer risk [32]. Progestin-
only users and levonorgestrel intrauterine system (LNG-
IUS) only users were also considered as non-users. Prescrip-
tions were sorted according to the Anatomical Therapeutic 
Chemical (ATC) Classification System; estrogen-only drugs, 
ATC group G03C and combined estrogen–progestin drugs, 
ATC group G03F.
Tumor histopathology
Information on tumor histology, grade, tumor size (T), nodal 
status (N), distant metastases (M), and hormone receptor 
(estrogen and progesterone; ER, PR) status were collected 
from pathology reports. For those cases from which tumor 
tissue microarray samples were available (42.6% of the cases 
in the current study), grade and histological type were fur-
ther verified by an experienced breast cancer pathologist 
(P.H.). Tumors were categorized histologically as ductal, 
lobular, and “other” for the purposes of this analysis. Grad-
ing was based on a modification of Scarff-Bloom-Richard-
son into grade 1–3 [33]. Ki67 expression was determined 
using immunohistochemistry, and scored as follows: 0 (neg-
ative; <5% cells positive), 1 (weak; 5–19%), 2 (intermediate; 
20–29%) and 3 (strong; >29%) [34]. HER2 amplification 
was detected from tumor tissue samples using chromogenic 
in situ hybridization (CISH) or, in the absence of a CISH 
result, immunohistochemical staining of the Her-2 protein 
was used (in total, 87.8% of all HER2 data originated from 
CISH).
Follow‑up data
The genealogies were confirmed through population reg-
istries and cancer diagnoses were confirmed through The 
Finnish Cancer Registry, a centralized registry that collects 
comprehensive diagnostic, mortality, and cause-of-death 
information on all cancer cases in Finland. Cancer diagno-
ses were also checked through hospital records. The sur-
vival was calculated as the time from the diagnosis of the 
first invasive breast cancer to diagnosis of a relapse (local 
recurrence free survival; LRFS), or of a distant metastasis 
(distant disease free survival; DDFS), or until death from 
breast cancer before March 1, 2011 (BCS). Survival times 
were censored at the date of last clinical follow-up for LFRS 
and DDFS, the date of last Finnish Cancer Registry update 
(March 1, 2011) for BCS, or the diagnosis date of a second 
primary cancer for all end-points.
Statistical analysis
The data were analyzed using SPSS Statistics 22 and R 3.0.2. 
P values for comparisons of HT usage and tumor character-
istics were calculated using linear and logistic regression as 
tests of heterogeneity and trend where appropriate. Hetero-
geneity between familial and sporadic cases was assessed by 
z-tests between coefficients from the corresponding regres-
sion models in Table 1, and as the significance of the beta of 
the interaction-term in the interaction analyses in Tables 2 
and 3. P values < 0.05 were considered statistically signifi-
cant and all p values are two-sided.
We used Cox regression analysis to estimate the asso-
ciation between HT and survival among familial and non-
familial cases, adjusted for age at diagnosis. Follow-up 
times were left-truncated to account for case recruitment 
latency (time between diagnosis and study entry). Cases 
with metastases at the time of diagnosis were excluded 
from the analysis. To investigate the effects of known 
prognostic factors, we also calculated additional Cox 
models that included ER, T, N, and grade, as well as 
age at diagnosis. The end points in the survival analy-
ses were BCS (death from breast cancer), distant disease 
free survival (DDFS) and local recurrence free survival 
(LRFS). The follow-up times for DDFS and LRFS were 
right-censored at 6 years; this threshold was chosen based 
on the observation that while regular clinical follow-up 
continues for 5 years after diagnosis, in principle, in actual 
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practice the last follow-up date is often during the 6th year. 
BCS follow-up times were right-censored at 10 years to 
avoid statistical problems relating to a diminishing pool 
or survivors (and an increasing rate of any-cause mor-
tality at long follow-up times). To maximize statistical 
power, it was considered ideal to investigate estrogen-only 
and estrogen–progestin combinations as a single group in 
the survival analysis. The feasibility of this approach was 
tested using a sensitivity analysis where HT use was split 
into three subcategories: estrogen-only, estrogen–proges-
tin, and mixed HT (e.g. estrogen-only followed by estro-
gen–progestin at a later date). Kaplan–Meier curves were 
Table 1  Clinicopathological 
features of breast cancer 
tumours of postmenopausal 
non-familial and familial breast 
cancer patients
a Percent of total, not included in the statistical analysis
Non-familial cases Familial cases
No HT (%) HT (%) p value no HT (%) HT (%) p value p (het)
Total 492 (51.7) 460 (48.3) 317 (54.3) 267 (45.7) 0.32 
Age at dg
(Mean) 64.6 61.5 < 0.0001 63.6 61.0 0.0009 0.50
ER status
Negative 88 (18.3) 58 (12.9) 0.02 45 (15.2) 54 (21.6) 0.051 0.004
Positive 392 (81.7) 393 (87.1) 251 (84.8) 196 (78.4)
Missinga 12 (2.4) 9 (1.95) 21 (6.62) 17 (6.36)
PgR status
Negative 166 (34.6) 170 (37.7) 0.32 94 (31.9) 98 (39.2) 0.076 0.41
Positive 314 (65.4) 281 (62.3) 201 (68.1) 152 (60.8)
Missing 12 (2.43) 9 (1.95) 22 (6.94) 17 (6.36)
Grade
1 128 (26.8) 158 (35.8) < 0.0001 75 (25.0) 80 (31.6) 0.35 0.067
2 214 (44.9) 208 (47.2) 149 (49.7) 107 (42.3)
3 135 (28.3) 75 (17.0) 76 (25.3) 66 (26.1)
Missing 15 (3.04) 19 (4.13) 17 (5.36) 14 (5.24)
T
T1 262 (53.8) 324 (70.9) < 0.0001 198 (64.1) 179 (67.8) 0.28 0.029
T2 186 (38.2) 109 (23.9) 90 (29.1) 71 (26.9)
T3 15 (3.1) 13 (2.8) 12 (3.9) 9 (3.4)
T4 24 (4.9) 11 (2.4) 9 (2.9) 5 (1.9)
Missing 5 (1.01) 3 (0.65) 8 (2.52) 3 (1.12)
N
N0 239 (49.5) 278 (61.0) 0.0004 163 (53.1) 150 (56.8) 0.37 0.14
N1 244 (50.5) 178 (39.0) 144 (46.9) 114 (43.2)
Missing 9 (1.82) 4 (0.86) 10 (3.15) 3 (1.12)
Histology
Ductal 356 (72.4) 274 (59.6) 215 (67.8) 164 (61.4)
Lobular 80 (16.3) 130 (28.3) < 0.0001 63 (19.9) 60 (22.5) 0.29 0.05
Other 56 (11.4) 56 (12.2) 0.2 39 (12.3) 43 (16.1) 0.13 0.74
Missing 0 (0.0) 0 (0.0) 0 (.00) 0 (0.0)
Ki67 score
0 64 (14.6) 117 (27.8) < 0.0001 64 (23.5) 62 (27.2) 0.63 0.001
1 184 (41.9) 202 (48.0) 116 (42.6) 90 (39.5)
2 96 (21.9) 46 (10.9) 46 (16.9) 38 (16.7)
3 95 (21.6) 56 (13.3) 46 (16.9) 38 (16.7)
Missing 53 (10.77) 39 (8.47) 45 (14.19) 39 (14.6)
Her2 status
Negative 196 (87.1) 166 (85.6) 0.65 179 (84.4) 156 (88.1) 0.29 0.28
Positive 29 (12.9) 28 (14.4) 33 (15.6) 21 (11.9)
Missing 267 (54.26) 266 (57.82) 105 (33.12) 90 (33.7)
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used to further visualize the association between HT and 
survival in relation to family status.
Results
Of all the study participants, 1536 cases were classified as 
postmenopausal women with diagnosis of invasive breast 
cancer at or over 50 years of age and included to this analy-
sis, as previously explained. Women were considered to be 
users of HT (n = 813) if they reported use of HT for more 
than 3 months. They were considered to be current-users 
(n = 727; 89%) if they reported use at date of diagnosis or 
within 12 months prior to the date of diagnosis of breast can-
cer. Of the current HT users, 166 (23%) had used an estro-
gen-only regimen, 246 (34%) had used estrogen–progestin 
combination therapy, and 314 (43%) had used mixed regi-
mens (switched between estrogen-only and estrogen–proges-
tin regimens. Although there was no statistically significant 
heterogeneity in HT regimen distribution between familial 
and sporadic cases (p = 0.057, Chi square test), estrogen-
only regimens appeared to be somewhat more common 
among familial cases (27 vs. 20% in sporadics). Within 
the mixed category, estrogen-only preparations were also 
slightly more common (proportion of purchases as reported 
by the National Medical Reimbursement Registry) among 
familial cases, but the difference was not statistically signifi-
cant (44% of all purchases in sporadic, 50% in familial cases; 
p = 0.1028, Student’s t test). The mean age of the patients 
at the time of diagnosis of first invasive breast cancer was 
62.6 years (SD 9.1 years). Of all invasive tumors, 1149 
(66.3%) were ductal, 358 (20.7%) lobular and 225 (13.0%) 
Table 2  Interaction analysis of the combined effect of HT use and family history
Separate models are presented for 10-year BCS (death from breast cancer; deaths from other causes are censored), 6-year distant disease free 
survival (distant metastasis; DDFS) and 6-year local recurrence free survival (LRFS). All analyses are adjusted for age at diagnosis
Breast cancer specific (BCS) HR 95% CI p value
Model without interaction term
HT 0.84 (0.61–1.17) 0.31
Family history 0.88 (0.63–1.23) 0.451
Age at diagnosis 1.05 (1.03–1.06) < 0.0001
Model with interaction term
HT 0.61 (0.41–0.92) 0.02
Family history 0.56 (0.35–0.92) 0.022
Age at diagnosis 1.05 (1.03–1.06) < 0.0001
HT * Family history 2.6 (1.3–5.18) 0.007
Distant disease free (DDFS) HR 95% CI p value
Model without interaction term
HT 0.75 (0.55–1.02) 0.07
Family history 0.77 (0.55–1.09) 0.14
Age at diagnosis 1.03 (1.01–1.05) 0.0002
Model with interaction term
HT 0.57 (0.39–0.83) 0.004
Family history 0.5 (0.31–0.82) 0.006
Age at diagnosis 1.03 (1.01–1.05) 0.0002
HT * Family history 2.6 (1.3–5.19) 0.007
Local recurrence free (LRFS) HR 95% CI p value
Model without interaction term
HT 0.88 (0.5–1.55) 0.67
Family history 1.26 (0.71–2.24) 0.43
Age at diagnosis 1.01 (0.98–1.04) 0.60
Model with interaction term
HT 0.56 (0.27–1.18) 0.13
Family history 0.71 (0.3–1.68) 0.43
Age at diagnosis 1.01 (0.98–1.04) 0.59
HT * Family history 3.25 (0.99–10.66) 0.05
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other. Age at diagnosis was significantly associated with 
HT use, with mean age at diagnosis being lower in current-
users compared to non-users (61.7 vs. 63.3 years). This asso-
ciation between HT use and age at diagnosis was similar 
between familial and non-familial cases (no heterogeneity; 
Table 1). The likelihood of HT use did not associate with 
family history of breast cancer. Among non-familial patients, 
460 (48.3%) were current users of HT, and 267 (45.7%) of 
the familial cases were current users of HT. Mean starting 
age of HT use could not be accurately determined for the 
whole data set, as the information in the National Medical 
Reimbursement Registry starts in 1994, and a substantial 
proportion of the cases may have started HT before 1994. 
Among cases starting in 1995 or later, the mean starting age 
was 53 years in both familial and sporadic cases.
Analysis of clinicopathological features of breast 
cancers in familial and non‑familial by HT use
See Table 1 for a detailed breakdown of the clinicopatho-
logical features of breast cancer tumors among non-famil-
ial and familial breast cancer patients according to HT 
use. Among non-familial patients, current use of HT was 
associated with more favorable characteristics. Current 
users of HT were more likely to present with ER-positive 
tumors (p = 0.02), lobular histological type (p < 0.0005), 
tumors of lower grade (p = 0.001), less advanced T-stage 
(p < 0.0005), lower rate of nodal metastasis (p = 0.0004), 
and lower Ki-67 proliferative index (p < 0.0005).
In contrast, among familial cases HT use did not 
strongly associate with tumor phenotype. However, there 
was a significant heterogeneity in HT-phenotype associa-
tion when comparing familial and non-familial cases, par-
ticularly in the case of ER status  (p(het) = 0.0036), where 
non-familial HT-associated tumors tended to be ER-pos-
itive, and in Ki67 index  (p(het) = 0.0012), where familial 
HT-associated tumors had lower proliferation rates, as well 
as in tumour stage, where familial HT-associated cases had 
more advanced tumors (p = 0.03).
HT use associates with better prognosis 
among non‑familial but not among familial cases
Sensitivity analysis did not indicate significant hetero-
geneity between the prognostic values of estrogen-only, 
estrogen–progestin, and mixed HT either among familial 
(p = 0.44, Woolf’s test for heterogeneity) or non-familial 
(p = 0.92) cases (Supplementary Fig. 1). The regimens 
were therefore combined into a single category to define 
current HT use.
Among the non-familial cases, postmenopausal HT 
use was associated with better survival in BCS (HR 0.63, 
95% CI 0.41–0.94, p = 0.03) and DDFS (HR 0.58, 95% CI 
0.40–0.85, p = 0.005), with a similar but statistically non-
significant effect in LRFS (Fig. 2). This favorable prog-
nosis was not observed among familial cases, however. 
Among familial cases, HT was not associated with sur-
vival to a statistically significant degree, and the observed 
hazard ratios were in the opposite direction compared to 
non-familial cases. See Fig. 3 for a visual depiction of 
absolute BCS rates among familial and non-familial cases 
in relation to HT use.
Based on the results above, we tested for interaction 
between HT and family history (Table 2). The apparent 
heterogeneity between familial and non-familial cases was 
confirmed in the interaction analysis, with  p(interaction) values 
of 0.007 (BCS), 0.007 (DDFS). Again, LRFS statistics fol-
lowed a similar pattern but did not reach statistical signifi-
cance (p = 0.05).
In a multivariate interaction analysis (BCS), we observed 
a statistically significant (p = 0.04) increased hazard associ-
ated with the combination of HT and family history, despite 
adjustment for year of diagnosis and standard prognostic 
factors (ER, T, N, Grade, and age; Table 3).
Table 3  BCS interaction analysis adjusted for standard prognostic 
factors
Interaction analysis between HT use and family history using 10-year 
BCS (death from breast cancer; deaths from other causes are cen-
sored). Standard prognostic factors included are estrogen receptor 
status (ER), histological grade, tumor size coded as T stage, nodal 
metastasis coded as 0/1, and age at diagnosis. Additionally, year of 
diagnosis has been included as an additional covariate to account for 
different case recruitment periods
HR 95% CI p value
Model without interaction term
HT 1.04 (0.73–1.48) 0.81
Family history 0.67 (0.47–0.97) 0.04
Age at diagnosis 1.04 (1.02–1.06) < 0.0001
Year of diagnosis 0.89 (0.83–0.95) 0.0005
ER status 0.32 (0.21–0.48) < 0.0001
Grade 1.32 (1.01–1.73) 0.04
Tumor size 1.90 (1.57–2.29) < 0.0001
Nodal metastasis 2.68 (1.83–3.92) < 0.0001
Model with interaction term
HT 0.81 (0.53–1.25) 0.35
Family history 0.46 (0.27–0.79) 0.005
Age at diagnosis 1.04 (1.02–1.06) < 0.0001
Year of diagnosis 0.89 (0.83–0.95) 0.0004
ER status 0.33 (0.22–0.50) < 0.0001
Grade 1.31 (1.00–1.71) 0.05
Tumor size 1.90 (1.57–2.30) < 0.0001
Nodal metastasis 2.68 (1.83–3.91) < 0.0001
HT * Family history 2.20 (1.05–4.63) 0.04
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A sensitivity analysis (Supplementary Fig. 1) did not 
indicate any major difference between HT-regimens and 
prognostic interaction.
Discussion
We have investigated the relationship between hormone 
therapy, family history, and breast cancer prognosis. Our 
results suggest that the association between HT and prog-
nosis may be influenced by family history: while sporadic 
breast cancers developing during HT tend to have favorable 
prognosis, in familial cases HT use either does not associate 
with prognosis at all, or may lead to slightly worse survival. 
Consistent with our findings in sporadic cases, most previ-
ous observational studies indicate that the breast cancers 
diagnosed during HT are less aggressive with higher his-
tological differentiation [4, 9–23]. HT has been associated 
Fig. 2  Survival statistics for 
HT users compared to non-users 
among sporadic and familial 
breast cancer cases. The end 
points in the analyses are BCS 
(death from breast cancer; 
deaths from other causes are 
censored; all follow-up times 
are censored at 10 years), 
distant disease free survival 
(distant metastasis; DDFS) and 
local recurrence free survival 
(LRFS). For DDFS and LRFS, 
follow-up times are censored 
at 6 years. All analyses are 
adjusted for age at diagnosis
HR
0.40 1.00 2.51
HR 95% C.I. p-value 
0.63 (0.41 - 0.94) 0.024952 
0.58 (0.40 - 0.85) 0.005264 
0.58 (0.27 - 1.21) 0.145979 
1.53 (0.86 - 2.71) 0.144115 
1.39 (0.77 - 2.52) 0.272187 














































Fig. 3  Kaplan–Meier curves illustrating breast cancer specific sur-
vival according to HT use. Breast-cancer specific (BCS) survival 
curves are depicted for a sporadic and b familial breast cancer cases 
according to HT use at the time of diagnosis. Follow-up times are 
left-truncated to account for recruitment latency, and right-censored 
at a maximum of 10 years of follow-up
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with low-grade, mostly hormone-receptor positive invasive 
cancers and lobular histology, and HT-related breast cancers 
tend to have better prognosis. In the studies where informa-
tion on regimen was available [13, 16, 18, 21] both patients 
on estrogen only and estrogen combined with progestin were 
included; the majority, approximately 80%, had combina-
tion therapy. However, these findings were not confirmed in 
the first randomized placebo-controlled trial, he Women’s 
Health Initiative (WHI), where combined HT was associated 
with more advanced cancer at diagnosis and worse progno-
sis, while estrogen only was associated with an improved 
prognosis and more favorable tumor characteristics [7]. The 
reason for the discrepancy between breast cancer character-
istics in the combined HT group in the WHI study and the 
majority of previous observational studies remains unclear. 
Although a randomized study, the WHI trial did not include 
a randomization between estrogen only and combined HT. 
Instead, the treatment arm was chosen based on previous 
history of hysterectomy. It is therefore possible that the dif-
ference in tumor characteristics and prognosis between these 
two HT regimens may be influenced by confounding factors 
in addition to the effect of the HT regimen per se.
There is little previous data available on the effect of pre-
vious HT use in women with a family history of breast can-
cer. The Iowa Women’s health study was the first to inves-
tigate the role of family history in combination with HT: in 
this study, HT users with a family history had a significantly 
lower hazard of all-cause mortality than never-users, but not 
when death from breast cancer was used as the end-point. 
The breast-cancer specific hazard in fact appeared to have 
increased in association with HT use, although this was not 
statistically significant, and the statistical confidence inter-
vals were wide (RR 1.9; 95% CI 0.6–5.7) [24].
Our results are consistent with most previous obser-
vational studies in that HT use appears to associate with 
more favorable tumor characteristics and better prognosis 
in cases without family history. However no such protective 
effect was seen among cases with family history. Indeed, in 
familial cases HT use appeared to associate with increased 
hazard, although not to a statistically significant degree. 
This observation was statistically verified by an interaction 
test, which indicated that the prognosis associated with HT 
use is modulated by family history using either death from 
breast cancer (BCS) or distant metastasis (DDFS) as sur-
vival end-points. We also detected statistically significant 
phenotypic heterogeneity between familial and non-familial 
cases, particularly in the case of ER status and Ki67 pro-
liferative index. As the association between HT and tumor 
characteristics differed between familial and non-familial 
cases, the association between HT and survival can be par-
tially expected to arise from differences in tumor histopa-
thology: the tumors of familial HT users exhibit markers 
of worse prognosis (ER-negativity and proliferation). The 
association between HT and survival does not appear to be 
entirely explained by these prognostic markers, however, 
since multivariate analysis still showed a statistically sig-
nificant interaction.
The large randomized WHI study indicated biological 
differences between estrogen-only and estrogen–progestin 
therapy: estrogen-only therapy may be associated with an 
improved breast cancer prognosis, whereas combined estro-
gen–progestin therapy may in contrast be associated with 
increased mortality and adverse prognostic features [7, 8]. 
The WHI trial included a substantial proportion of women 
with familial history, between 11.8 and 14.2% in the differ-
ent treatment groups, but no separate analyses of familial 
cases were reported. It was therefore important to consider 
the possibility that our results may be confounded by differ-
ences in HT regimens between familial and sporadic cases. 
Our study included patients on estrogen therapy alone, 
estrogen–progestin combination therapy, and a large subset 
(43%) of cases who had switched one or more times between 
estrogen and estrogen–progestin regimens (mixed category). 
The mixed category may in reality be even larger, since we 
do not have data from before 1994. Due to the smaller num-
ber of patients in the regimen-specific subgroups, it was not 
feasible to conduct comprehensive analyses of these groups 
separately with sufficient statistical power. However, a sen-
sitivity analysis (Supplementary Fig. 1) did not indicate any 
major differences in prognosis between these categories. It 
must be noted that while the distributions of HT regimens 
were similar between familial and sporadic cases, estrogen-
only regimens were nevertheless somewhat more common 
among the familial cases in our study. Similarly, the distribu-
tions of specific HT drug types within the “mixed” category 
were also very similar between familial and non-familial 
cases, yet estrogen-only preparations were slightly more 
common among familial cases. These minor differences are 
unlikely to have biased our results towards worse progno-
sis among familial cases, given that estrogen-only HT has 
been reported to associate with better prognosis compared 
to combination therapies.
A major strength of the present study is the availability 
of accurate patient data through the uniform, centralized 
Finnish health care system. Detailed data on tumor histopa-
thology and follow-up data could be obtained from clinical 
records and the nationwide Finnish Cancer Registry, and 
reliable, detailed information on systemic hormone therapy 
obtained from the National Medical Reimbursement Regis-
try of the Social Insurance Institution during the period of 16 
years, ranging from beginning of 1994 until the end of 2009. 
Data from National Medical Reimbursement Registry cover 
practically 100% of all HT users because HT is available 
only on medical prescription in Finland. Moreover, since HT 
use was based on registry data in contrast to patient reported 
data, the effect of patient recall bias is eliminated. One minor 
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limitation of this study is that accurate time of exposure to 
HT regimen could not be calculated for patients who were 
using HT already in 1994, when the Reimbursement Reg-
istry of the Social Insurance Institution was established. 
For these patients we cannot be sure of the accurate time of 
exposure to HT, which prevents the reliable inclusion of past 
use and the duration of use as parameters in the analyses. 
We have therefore restricted our analyses to current-use only, 
and to patients diagnosed after 1994.
The most important limitations of this study arise from 
the observational nature of this investigation. Lifestyle fac-
tors cannot be entirely accounted for or excluded as con-
founders. It must also be noted that we cannot rule out a 
degree of potential selection bias in our study since the 
majority of our familial cases have been collected specifi-
cally from patients attending clinical genetics counseling 
due to the suspicion of familial disease, whereas the sporadic 
patients were recruited as unselected consecutive patients 
during a limited time-period. All these sporadic cases have, 
however, been interviewed for family history. Both family 
history and HT use can also influence the patients’ lifestyle, 
such as the frequency of mammography screening, for which 
we do not have available data. However, population-based 
mammography screening has been available in Finland since 
1987 among women aged 50–69, which probably minimizes 
any bias in breast screening between HT users and non-users 
in our cohort. Moreover, the cancers in the familial and non-
familial HT users in our study display differential biological 
characteristics, notably ER status, in addition to differences 
in survival times, which is not to be expected had the adverse 
prognosis of HT users in the familial cases been due to life-
style factors.
Conclusions
Our results suggest that a positive family history of breast 
cancer may predispose users of postmenopausal hormone 
therapy to breast cancer with a more aggressive phenotype 
and worse prognosis compared to HT users without family 
history. If confirmed by further studies, our results suggest 
that family history should be taken into consideration in clin-
ical counseling before beginning a HT regimen. Physicians 
should discuss the benefits and risks of HT with women in 
the context of their own personal or family history, so that 
they can make informed decisions about initiating or con-
tinuing HT use.
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